CN117958432A - Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof - Google Patents
Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof Download PDFInfo
- Publication number
- CN117958432A CN117958432A CN202410271821.2A CN202410271821A CN117958432A CN 117958432 A CN117958432 A CN 117958432A CN 202410271821 A CN202410271821 A CN 202410271821A CN 117958432 A CN117958432 A CN 117958432A
- Authority
- CN
- China
- Prior art keywords
- potassium alginate
- trehalose
- gastric
- chaperone
- sodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000737 potassium alginate Substances 0.000 title claims abstract description 116
- 235000010408 potassium alginate Nutrition 0.000 title claims abstract description 116
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 title claims abstract description 109
- 108010006519 Molecular Chaperones Proteins 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 70
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 70
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 63
- 239000011734 sodium Substances 0.000 claims abstract description 37
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 29
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 13
- -1 potassium alginate sodium salt Chemical class 0.000 claims abstract description 10
- 125000000647 trehalose group Chemical group 0.000 claims abstract description 7
- 235000013373 food additive Nutrition 0.000 claims abstract description 5
- 239000002778 food additive Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 11
- 238000004090 dissolution Methods 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 abstract description 28
- 159000000000 sodium salts Chemical class 0.000 abstract description 14
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract description 13
- 239000000661 sodium alginate Substances 0.000 abstract description 13
- 235000010413 sodium alginate Nutrition 0.000 abstract description 13
- 229940005550 sodium alginate Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 6
- 238000006467 substitution reaction Methods 0.000 abstract description 5
- 230000003203 everyday effect Effects 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 238000009138 potassium supplementation Methods 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 235000015598 salt intake Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 19
- 238000000889 atomisation Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 210000004051 gastric juice Anatomy 0.000 description 7
- 238000001035 drying Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000011258 core-shell material Substances 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the field of food additives, and particularly relates to a gastric-soluble potassium alginate sodium-lowering salt partner, and a preparation method and application thereof. The gastric-soluble potassium alginate sodium salt chaperone is prepared from potassium alginate and trehalose, wherein the potassium alginate accounts for 60-85% of the total mass of the raw materials, and the balance is trehalose, and the trehalose is coated on the surface of the potassium alginate. According to the invention, the trehalose is coated on the surface of the potassium alginate, so that the insoluble property of the potassium alginate is improved, the potassium alginate is soluble in the stomach, can effectively participate in the substitution reaction of Na +, and generates K + to generate insoluble sodium alginate, and the insoluble sodium alginate is discharged out of the body, so that the effect of effectively reducing sodium and simultaneously completing potassium supplementation is realized. The intake of sodium salt reducing companion (3-5 g) can be reduced by a small amount every day, so that 95% of sodium salt intake can be reduced, and cardiovascular and cerebrovascular risks caused by excessive salt can be effectively reduced.
Description
Technical Field
The invention belongs to the field of food additives, and particularly relates to a gastric-soluble potassium alginate sodium-lowering salt partner, and a preparation method and application thereof.
Background
A large number of researches show that excessive intake of edible salt is harmful to body health, not only can the kidney be injured to cause edema, but also the risks of diseases such as hypertension, hyperlipidemia, heart disease, cerebral apoplexy and the like can be increased. 95% of the salt is removed by renal filtration through the blood.
Patent application CN105433345A discloses a novel preparation method of nutritional low sodium salt, patent application CN105285903A discloses an amino acid low sodium salt composition, low sodium salt food and a preparation method thereof, patent application CN111671073A discloses a preparation method of low sodium salt, patent application CN113753920B discloses a selenium-rich low sodium salt and a preparation method thereof, and the selenium-rich low sodium salt belongs to salt substitution products, and sodium intake is reduced only by adding non-sodium salt or other flavor substances, sodium reduction is low, and meanwhile, due to large taste change, consumption habit and other factors, the selenium-rich low sodium salt is not effectively popularized.
Patent application CN201310178261 discloses an edible salt with health care function, and proposes to spray potassium alginate solution on edible salt and potassium chloride salt to prepare potassium alginate mixed salt, and to try to replace Na + in the edible salt by using potassium alginate, but the solution is sprayed on NaCl salt to react with NaCl immediately to generate sodium alginate, so that the sodium alginate is deactivated, the Na + replacement function is completely lost before the sodium alginate enters human body, meanwhile, the salinity of the edible salt is reduced to a certain extent, the adding amount of the sodium alginate is increased, and the sodium reduction effect is not achieved at all.
Patent application CN104222999a discloses a composition, preparation and use of a novel low sodium salt, which is prepared by mixing NaCl salt and potassium alginate to prepare a compound salt, so that it is hoped to realize sodium and potassium reduction in human body, but the following defects exist, which lead to the fact that the purposes cannot be really realized:
1. the hygroscopicity of sodium salt can lead to the early reaction and deactivation of potassium alginate and sodium salt, and the hardening failure.
2. Potassium alginate has poor solubility, can be slowly dissolved by water with hundreds of times of the self weight, and is difficult to be effectively dissolved in gastric juice of human body.
3. The salt reduces the salty degree by replacing NaCl with part of potassium alginate, so that the adding amount of the edible salt is increased, and meanwhile, sticky gel is formed in the cooking process, so that the shape and the taste of food and soup products are changed.
Disclosure of Invention
Based on the technical background, the main purpose of the invention is to provide a gastric-soluble potassium alginate sodium-lowering salt partner and a preparation method and application thereof, so as to overcome the defects in the prior art.
In order to achieve the purpose of the invention, the technical scheme adopted by the invention comprises the following steps:
the invention provides a gastric-soluble potassium alginate sodium-lowering salt partner, which is prepared from potassium alginate and trehalose as raw materials, wherein the trehalose is coated on the surface of the potassium alginate.
Preferably, the total weight of the raw materials is 100 percent, the potassium alginate accounts for 60 to 85 percent of the total weight of the raw materials, and the balance is trehalose.
More preferably, the potassium alginate accounts for 70-80% based on 100% of the total weight of the raw materials, and the balance is trehalose.
Preferably, the molecular weight of the potassium alginate is 1500-3000 daltons, and the average particle size is 80-180 meshes.
Preferably, the average particle size of the gastric-soluble potassium alginate sodium salt-reducing chaperone is 350-550 mu m.
In a second aspect, the present invention provides a method for preparing the gastric-soluble potassium alginate sodium-lowering chaperone according to the first aspect of the invention, the method comprising the steps of:
Step 1, dissolving trehalose in water to obtain a trehalose solution;
And step 2, atomizing and coating the trehalose solution on the surface of the potassium alginate by spraying liquid, thus obtaining the gastric-soluble potassium alginate sodium salt-reducing chaperone.
Preferably, in step 1, the mass ratio of trehalose to water is 1: (1-2).
The trehalose is put into water and heated to 35-55 ℃ for full dissolution.
Preferably, in the step 2, adding potassium alginate into a powder device, adding trehalose solution into a liquid spraying and atomizing device, and coating the trehalose solution on the surface of the potassium alginate through the liquid spraying and atomizing device;
The inlet temperature of the spray atomizing device is set to be 40-65 ℃ and the outlet temperature is set to be 45-65 ℃.
The third aspect of the invention provides an application of the gastric-soluble potassium alginate sodium salt-reducing chaperone in the field of food additives.
The invention has the beneficial effects that:
(1) The gastric-soluble potassium alginate sodium-lowering salt chaperone is prepared from potassium alginate and trehalose, wherein the trehalose is coated on the surface of the potassium alginate, the insoluble property of the potassium alginate is modified by adopting the trehalose coating, so that the potassium alginate sodium-lowering salt chaperone is soluble in the stomach, can effectively participate in the substitution reaction of Na +, generate K +, generate insoluble sodium alginate, and discharge the insoluble sodium alginate out of the body, thereby realizing the effect of effectively lowering sodium and simultaneously completing potassium supplementation. The gastric-soluble potassium alginate sodium salt-lowering chaperone can be taken in a small amount (3-5 g) every day, so that 95% of sodium chloride intake can be reduced, and cardiovascular and cerebrovascular risks caused by excessive salt are effectively reduced.
(2) The trehalose used in the gastric-soluble potassium alginate sodium salt-reducing chaperone is natural sugar, is edible sugar for diabetics, can be used as a sweetener, a moisture-absorbing agent, a browning inhibitor, a fishy smell inhibiting deodorant and the like, and is widely used in the field of foods. The research shows that the trehalose also has the function of preventing the decomposition of grease, can reduce the digestion and absorption of the grease in human bodies, particularly can inhibit the decomposition of fatty acid and palmitic acid in sebum of middle-aged and elderly people, and can prevent the generation of heavy body taste of the middle-aged and elderly people.
(3) The gastric-soluble potassium alginate sodium salt-reducing companion does not participate in the cooking process, is convenient to use, has accurate and controllable dosage, and can be optionally drunk or orally taken before and after dining;
The gastric-soluble potassium alginate sodium salt-reducing chaperone disclosed by the invention does not belong to salt substitution or compound salt products, is not combined with salt in vitro, does not lose the function of replacing Na +, does not change the salt component, the taste and the use habit, and does not increase the addition amount of edible salt.
(4) According to the preparation method, trehalose is pre-dissolved in water and uniformly sprayed on the surfaces of potassium alginate microparticles, the potassium alginate absorbs sugar liquid to cause micro-swelling, part of small molecule sugar liquid enters potassium alginate microparticles to form a hydrophilic structure, the other part of sugar liquid forms a coating, the coating is dried to form a film, the film is dissolved in water, and the coated potassium alginate has the characteristics of non-caking, non-agglomeration and instant dissolution in gastric juice.
(5) According to the invention, trehalose is coated on the surface of potassium alginate in a liquid spraying atomization mode, and the method can enable the trehalose coated on the surface of potassium alginate to be more uniform and have a fluffy structure, so that the trehalose is extremely easy to dissolve in gastric juice, the gastric dissolution problem is solved, the activity of Na + is not influenced, na + in edible salt in gastric juice can be effectively replaced, insoluble sodium alginate is formed, and the sodium alginate is discharged out of the body.
Drawings
FIG. 1 shows a dynamic diagram of the dissolution of a gastric-soluble potassium alginate sodium-lowering chaperone in gastric juice;
FIG. 2 shows the core-shell formation process of gastric-soluble potassium alginate sodium salt-reducing chaperone in the preparation of example 1;
FIG. 3 shows a scanning electron micrograph of a gastric-soluble potassium alginate sodium salt-reduced chaperone prepared in example 1;
FIG. 4 shows a scanning electron micrograph of the product obtained in comparative example 1.
Detailed Description
The features and advantages of the present invention will become more apparent and evident from the following detailed description of the invention.
The first aspect of the invention provides a gastric-soluble potassium alginate sodium-lowering salt partner which is prepared from raw materials including, by weight, 100% of potassium alginate and trehalose, wherein the potassium alginate accounts for 60% -85% of the total mass of the raw materials, the potassium alginate accounts for 70% -80% of the total mass of the raw materials, and the balance is trehalose.
In the gastric-soluble potassium alginate sodium salt-reducing chaperone, trehalose is coated on the surface of potassium alginate.
The invention eliminates the traditional method of reducing sodium by changing the composition of edible salt NaCl, adopts gastric-soluble potassium alginate to directly replace Na + in human body to form insoluble sodium alginate, discharges outside the body and realizes effective sodium reduction.
The average particle size of the gastric-soluble potassium alginate sodium-lowering salt partner is 350-550 mu m, preferably 400-500 mu m.
The potassium alginate is low molecular weight oligosaccharide, the molecular weight is 1500-3000 daltons, the average particle size is 80-180 meshes, and the preferred average particle size is 120 meshes.
The trehalose is low in hygroscopicity, has relatively stable activity and is produced by a fermentation method.
The potassium alginate has extremely strong agglomeration, is difficult to dissolve in gastric juice, adopts pre-dissolution and then is mixed with other edible substances, and can exchange with Ca 2+、Na+、Mg2+、Al3+、Zn2+ and the like to lose efficacy. Trehalose is very soluble in water, does not contain any metal ions, does not react with potassium alginate, and is beneficial to human body. According to the invention, the traditional salt replacing and compound salt technology is abandoned, and a layer of trehalose is uniformly sprayed on the surface of potassium alginate particles through an atomization drying technology, so that the gastric dissolution problem is solved, and the activity of Na + replacement is not influenced, so that the potassium alginate is an optimal sodium salt reducing companion. Experiments show that the intake of sodium chloride can be reduced by 95% by taking a small amount (3-5 g) every day.
The dissolution dynamic diagram of the gastric-soluble potassium alginate sodium-lowering chaperone in gastric juice is shown in figure 1, after low-molecular potassium alginate is taken, the volume of the potassium alginate swells under the action of gastric acid to form an ascending trend, then the potassium alginate begins to dissolve and gelatinize, the potassium alginate becomes alginic acid, the particle form gradually disappears, finally the potassium alginate is completely dissolved and gradually becomes amorphous flocculus, potassium ions are absorbed into blood to supplement the potassium content in cells, the alginic acid enters intestinal tracts, sodium ions are absorbed from intestinal mucosa cells and become sodium alginate, the sodium alginate absorbs enough water in the intestinal tracts to become a part of excrement and simultaneously absorbs some toxins in large intestines, and the potassium alginate is discharged out of the body, so that the blood pressure of a hypertensive patient is reduced.
In a second aspect, the present invention provides a method for preparing the gastric-soluble potassium alginate sodium-lowering chaperone according to the first aspect of the invention, the method comprising the steps of:
Step 1, dissolving trehalose in water to obtain a trehalose solution;
And step 2, atomizing and coating the trehalose solution on the surface of the potassium alginate by spraying liquid, thus obtaining the gastric-soluble potassium alginate sodium salt-reducing chaperone.
The above steps are specifically described below.
In the step 1, the mass ratio of the trehalose to the water is 1: (1-2), preferably the mass ratio is 1:1.
The trehalose is placed in water and heated to 35-55 ℃ for full dissolution, preferably, the trehalose is placed in water and heated to 40-50 ℃ for full dissolution.
In the step 2, the trehalose solution is preferably coated on the surface of the potassium alginate by adopting a coating type fluidized bed granulation atomization dryer.
More preferably, the potassium alginate is added into the powder device, the trehalose solution is added into the spray atomization device, and the trehalose solution is coated on the surface of the potassium alginate through the spray atomization device.
The inlet temperature of the spray atomizing device is set to be 25-65 ℃ and the outlet temperature is set to be 45-65 ℃. The temperature is too low, the particle size is too large, the temperature is too high, and the particle size is too fine.
Preferably, the inlet temperature of the spray atomizing device is set to 45-60 ℃ and the outlet temperature is set to 50-60 ℃. The temperature is too high or too low to ensure that the trehalose is uniformly coated on the surface of the potassium alginate.
The third aspect of the invention provides an application of the gastric-soluble potassium alginate sodium salt-reducing chaperone in the field of food additives.
Examples
The invention is further illustrated by the following specific examples, which are intended to be illustrative of the invention and are not intended to limit the scope of the invention.
The raw materials adopted in the embodiment of the invention are all purchased.
Example 1
Weighing potassium alginate (average particle size of 120 meshes) and trehalose according to a mass ratio of 75:25.
Mixing and dissolving the weighed trehalose and pure water according to the mass ratio of 1:1, wherein the dissolving temperature is 45 ℃, and fully dissolving to obtain the trehalose solution.
Adopting a coating type fluidized bed granulation atomization dryer, adding potassium alginate into a powder device, adding trehalose solution into a liquid spraying atomization device, setting the inlet temperature to 45 ℃, controlling the particle size to about 400 microns, and controlling the outlet temperature to 50 ℃. And starting equipment to finish atomization drying, and performing cyclone separation and collection to obtain the finished gastric-soluble potassium alginate sodium salt-reducing chaperone.
The obtained product is divided into small bags of 3g per bag, which is convenient for drinking.
The core-shell forming process of the gastric-soluble potassium alginate sodium salt chaperone is shown in figure 2, wherein figure A is potassium alginate microparticles, figure B is trehalose to start coating the potassium alginate microparticles, and figure C is the coating process to form a core-shell structure; in the graph D, the gastric-soluble potassium alginate sodium-lowering salt partner finished product is formed after dispersion.
The scanning electron microscope picture of the gastric-soluble potassium alginate sodium salt chaperone is shown in figure 3, and the gastric-soluble potassium alginate sodium salt chaperone is smooth in surface, uniform in particle size and uniformly coated on the surface of the potassium alginate from figure 3.
Example 2
Weighing potassium alginate (average particle size of 120 meshes) and trehalose according to the mass ratio of 70:30.
Mixing and dissolving the weighed trehalose and pure water according to the mass ratio of 1:1, wherein the dissolving temperature is 50 ℃, and fully dissolving to obtain the trehalose solution.
Adopting a coating type fluidized bed granulation atomization dryer, adding potassium alginate into a powder device, adding trehalose solution into a liquid spraying atomization device, setting the inlet temperature to 60 ℃, controlling the particle size to be about 500 microns, and controlling the outlet temperature to be 60 ℃. And starting equipment to finish atomization drying, and performing cyclone separation and collection to obtain the finished gastric-soluble potassium alginate sodium salt-reducing chaperone.
The obtained product is pressed into 2g of tablet products for each tablet, and is convenient for oral administration.
Example 3
Weighing potassium alginate (average particle size of 120 meshes) and trehalose according to the mass ratio of 80:20.
Mixing and dissolving the weighed trehalose and pure water according to the mass ratio of 1:1, wherein the dissolving temperature is 40 ℃, and fully dissolving to obtain the trehalose solution.
Adopting a coating type fluidized bed granulation atomization dryer, adding potassium alginate into a powder device, adding trehalose solution into a liquid spraying atomization device, setting the inlet temperature to 55 ℃, controlling the particle size to about 450 micrometers, and controlling the outlet temperature to 55 ℃. And starting equipment to finish atomization drying, and performing cyclone separation and collection to obtain the finished gastric-soluble potassium alginate sodium salt-reducing chaperone.
The obtained product is pressed into 2g of tablet products for each tablet, and is convenient for oral administration.
Comparative example
Comparative example 1
Weighing potassium alginate (average particle size of 120 meshes) and trehalose according to a mass ratio of 75:25.
Mixing and dissolving the weighed trehalose and pure water according to the mass ratio of 1:1, wherein the dissolving temperature is 45 ℃, and fully dissolving to obtain the trehalose solution.
And (3) placing the potassium alginate into trehalose solution for stirring and coating, filtering to obtain solid particles, and drying the solid particles at 50 ℃ to obtain the product.
As shown in the scanning electron microscope photograph of the product in figure 4, the surface of the product is rough, trehalose can not completely coat potassium alginate, the trehalose is unevenly distributed on the surface of the potassium alginate, and a core-shell structure can not be formed.
The invention has been described in detail in connection with the specific embodiments and exemplary examples thereof, but such description is not to be construed as limiting the invention. It will be understood by those skilled in the art that various equivalent substitutions, modifications or improvements may be made to the technical solution of the present invention and its embodiments without departing from the spirit and scope of the present invention, and these fall within the scope of the present invention. The scope of the invention is defined by the appended claims.
Claims (10)
1. The gastric-soluble potassium alginate sodium salt-reducing chaperone is characterized in that the gastric-soluble potassium alginate sodium salt-reducing chaperone is prepared from potassium alginate and trehalose as raw materials, and the trehalose is coated on the surface of the potassium alginate.
2. The gastric-soluble potassium alginate sodium salt-reducing chaperone of claim 1, wherein,
The total weight of the raw materials is 100 percent, the potassium alginate accounts for 60 to 85 percent of the total weight of the raw materials, and the balance is trehalose.
3. The gastric-soluble potassium alginate sodium salt-reducing chaperone of claim 2, wherein,
Based on the total weight of the raw materials as 100%, the potassium alginate accounts for 70% -80%, and the balance is trehalose.
4. The gastric-soluble potassium alginate sodium salt-reducing chaperone of claim 1, wherein,
The molecular weight of the potassium alginate is 1500-3000 daltons, and the average grain diameter is 80-180 meshes.
5. The gastric-soluble potassium alginate sodium salt-reducing chaperone of claim 1, wherein,
The average grain diameter of the gastric soluble potassium alginate sodium salt chaperone is 350-550 mu m.
6. A process for the preparation of a gastric-soluble potassium alginate sodium salt of chaperone according to any one of claims 1 to 5, characterised in that it comprises the steps of:
Step 1, dissolving trehalose in water to obtain a trehalose solution;
And step 2, atomizing and coating the trehalose solution on the surface of the potassium alginate by spraying liquid, thus obtaining the gastric-soluble potassium alginate sodium salt-reducing chaperone.
7. The method according to claim 6, wherein, in step 1,
The mass ratio of the trehalose to the water is 1: (1-2).
8. The method according to claim 6, wherein, in step 1,
The trehalose is put into water and heated to 35-55 ℃ for full dissolution.
9. The method according to claim 6, wherein, in step 2,
Adding potassium alginate into a powder device, adding trehalose solution into a liquid spraying and atomizing device, and coating the trehalose solution on the surface of the potassium alginate through the liquid spraying and atomizing device;
The inlet temperature of the spray atomizing device is set to be 40-65 ℃ and the outlet temperature is set to be 45-65 ℃.
10. Use of a gastric-soluble potassium alginate sodium salt-reducing chaperone according to any one of claims 1 to 5 in the field of food additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410271821.2A CN117958432A (en) | 2024-03-11 | 2024-03-11 | Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410271821.2A CN117958432A (en) | 2024-03-11 | 2024-03-11 | Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117958432A true CN117958432A (en) | 2024-05-03 |
Family
ID=90862654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410271821.2A Pending CN117958432A (en) | 2024-03-11 | 2024-03-11 | Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117958432A (en) |
-
2024
- 2024-03-11 CN CN202410271821.2A patent/CN117958432A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106420643B (en) | A kind of chewable tablets and preparation method thereof containing vitamine C sodium | |
| WO2016045309A1 (en) | New type of composition, preparation, and use of low-sodium salt | |
| WO1999001149A1 (en) | Health supplement | |
| US6887492B2 (en) | Magnesium plus interactive agent delivery | |
| JP2001522614A (en) | Extruded intermediate containing soluble fiber and food containing same | |
| WO2016045308A1 (en) | Application of oligomeric sodium alginate preparation in pharmaceuticals and health care products and salt products | |
| CN102511814B (en) | Composition with lipase inhibiting effect and application of same | |
| CN106420629B (en) | Branched-amino acid supplement and its preparation method and application | |
| CN106389344A (en) | Calcium carbonate particles and preparation method thereof | |
| CN107981351B (en) | Dietary microcapsule particle for regulating body fat rate and preparation method thereof | |
| WO1991004751A1 (en) | Inhibitor of absorption of digestion product of food and drink | |
| CN1903056B (en) | Xylitox coffee products for chewing or instant dissolving, and its prepn. method | |
| CN103143001A (en) | Bone collagen high calcium tablet | |
| JP2001316271A (en) | Chitosan containing composition | |
| CN108553426B (en) | Chitosan dropping pill and preparation method thereof | |
| JP5327682B2 (en) | Pharmaceutical composition used as laxative | |
| CN117958432A (en) | Gastric-soluble potassium alginate sodium-lowering chaperone and preparation method and application thereof | |
| CN102552871B (en) | A kind of tannalbin yeast chewable tablet and production method thereof | |
| CN1973682A (en) | Health food | |
| JPWO2002021941A1 (en) | New vinegar seaweed powder or granules and method for producing the same | |
| JP2003061618A (en) | Mineral-containing food composition | |
| WO2020241650A1 (en) | Sodium excretion particles | |
| JP5270893B2 (en) | Process for producing rapidly disintegrating granules containing off-flavor ingredients | |
| AU7121594A (en) | Dietary supplement based on soluble dietary fibers | |
| JP5585075B2 (en) | Growth hormone secretagogue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |